B. Kaplan Survivor’s Tru Karen Purchases 10,000 Shares of RadNet Inc. (NASDAQ:RDNT) Stock

RadNet Inc. (NASDAQ:RDNT) insider B. Kaplan Survivor’s Tru Karen bought 10,000 shares of the stock in a transaction dated Wednesday, March 18th. The stock was bought at an average price of $5.99 per share, with a total value of $59,900.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

RDNT stock opened at $9.72 on Thursday. The company has a fifty day moving average price of $18.46 and a 200 day moving average price of $17.90. RadNet Inc. has a 12 month low of $5.81 and a 12 month high of $23.45. The company has a market cap of $471.96 million, a price-to-earnings ratio of 30.03 and a beta of 0.93. The company has a debt-to-equity ratio of 4.62, a current ratio of 0.74 and a quick ratio of 0.74.

RadNet (NASDAQ:RDNT) last released its quarterly earnings results on Thursday, March 12th. The medical research company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.15 by $0.06. RadNet had a net margin of 1.28% and a return on equity of 7.32%. The firm had revenue of $300.80 million during the quarter, compared to the consensus estimate of $294.16 million. During the same quarter in the prior year, the firm earned $0.59 EPS. RadNet’s revenue for the quarter was up 16.9% on a year-over-year basis. As a group, analysts anticipate that RadNet Inc. will post 0.53 earnings per share for the current year.

Several brokerages have recently issued reports on RDNT. Sidoti upped their target price on shares of RadNet from $23.00 to $28.00 and gave the company a “buy” rating in a report on Friday, February 21st. Zacks Investment Research upgraded shares of RadNet from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a research report on Wednesday. ValuEngine downgraded shares of RadNet from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, BidaskClub downgraded shares of RadNet from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, March 17th. One analyst has rated the stock with a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $18.88.

Hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its position in RadNet by 1.2% in the 3rd quarter. California State Teachers Retirement System now owns 65,480 shares of the medical research company’s stock valued at $940,000 after purchasing an additional 782 shares during the last quarter. California Public Employees Retirement System raised its position in RadNet by 18.2% in the 3rd quarter. California Public Employees Retirement System now owns 70,187 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 10,800 shares during the last quarter. Zebra Capital Management LLC raised its position in RadNet by 35.5% in the 3rd quarter. Zebra Capital Management LLC now owns 14,077 shares of the medical research company’s stock valued at $203,000 after purchasing an additional 3,691 shares during the last quarter. State Street Corp raised its position in RadNet by 4.1% during the 3rd quarter. State Street Corp now owns 889,809 shares of the medical research company’s stock worth $12,778,000 after buying an additional 35,430 shares during the last quarter. Finally, Citigroup Inc. raised its position in RadNet by 1,653.5% during the 4th quarter. Citigroup Inc. now owns 96,864 shares of the medical research company’s stock worth $1,966,000 after buying an additional 91,340 shares during the last quarter. Hedge funds and other institutional investors own 72.14% of the company’s stock.

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

See Also: Gap Up Stocks

Insider Buying and Selling by Quarter for RadNet (NASDAQ:RDNT)

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.